Skip to main content
Fig. 3 | Journal of Hematology & Oncology

Fig. 3

From: Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study

Fig. 3

Overall survival of matched ZUMA-3 and SCHOLAR-3 treated patients. KaplanMeier OS estimates of ZUMA-3 and SCA patients who were previously naïve to blinatumomab and inotuzumab (SCA-1; A), patients who were previously treated with blinatumomab or inotuzumab (SCA-2, B) and all matched patients (SCA-combined; C). CR = complete remission. CRi = complete remission with incomplete hematological recovery. NE = not estimable

Back to article page